Empire Financial Management Company LLC Invests $307,000 in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Empire Financial Management Company LLC bought a new position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 64,000 shares of the biopharmaceutical company's stock, valued at approximately $307,000. Empire Financial Management Company LLC owned approximately 0.11% of Vanda Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its holdings in shares of Vanda Pharmaceuticals by 17.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock valued at $107,000 after purchasing an additional 3,370 shares during the period. Hsbc Holdings PLC boosted its holdings in Vanda Pharmaceuticals by 81.6% in the fourth quarter. Hsbc Holdings PLC now owns 48,049 shares of the biopharmaceutical company's stock worth $229,000 after acquiring an additional 21,584 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Vanda Pharmaceuticals by 10.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company's stock valued at $11,920,000 after acquiring an additional 227,428 shares during the period. Marshall Wace LLP bought a new stake in shares of Vanda Pharmaceuticals during the fourth quarter valued at approximately $387,000. Finally, Zacks Investment Management bought a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth $74,000. 88.14% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the company's stock in a transaction on Friday, February 28th. The shares were purchased at an average cost of $4.76 per share, for a total transaction of $47,600.00. Following the completion of the purchase, the chief executive officer now directly owns 2,361,730 shares in the company, valued at $11,241,834.80. The trade was a 0.43 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Over the last three months, insiders have acquired 32,000 shares of company stock worth $151,180. 8.90% of the stock is owned by company insiders.

Vanda Pharmaceuticals Stock Up 1.2 %

NASDAQ VNDA traded up $0.05 on Monday, reaching $4.30. The company had a trading volume of 446,043 shares, compared to its average volume of 770,048. The stock has a market capitalization of $250.76 million, a P/E ratio of -13.44 and a beta of 0.72. The company's fifty day moving average is $4.56 and its 200 day moving average is $4.68. Vanda Pharmaceuticals Inc. has a 52-week low of $3.85 and a 52-week high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The business had revenue of $53.19 million during the quarter, compared to the consensus estimate of $51.00 million. On average, research analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Analysts Set New Price Targets

VNDA has been the topic of several research reports. StockNews.com began coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a "hold" rating on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, April 1st.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.